Juan Antonio T.
Zoug, Zoug, Suisse
6 k abonnés
+ de 500 relations
Voir les relations en commun avec Juan Antonio
Juan Antonio peut vous mettre en relation avec plus de 10 personnes chez Madrigal Pharmaceuticals
ou
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
Voir les relations en commun avec Juan Antonio
ou
Nouveau sur LinkedIn ? Inscrivez-vous maintenant
En cliquant sur Continuer pour vous inscrire ou vous identifier, vous acceptez les Conditions d’utilisation, la Politique de confidentialité et la Politique relative aux cookies de LinkedIn.
À propos
With over 20 years of digital and IT expertise, my current role builds on my prior…
Activité
6 k abonnés
-
Juan Antonio T. a republié ceciJuan Antonio T. a republié ceciToday, I had the privilege of ringing the Nasdaq Closing Bell alongside our leadership team at Madrigal. It was an opportunity to celebrate 10 years as a public company and recognize the value that Madrigal has created for our shareholders, our employees and, most of all, patients living with MASH. I'm grateful to everyone who helped get us here and proud of what we’ve built together. The work ahead is just as important as the work behind us, and we remain relentless in Leading the Fight Against MASH.
-
Juan Antonio T. a republié ceciJuan Antonio T. a republié ceciMFN pricing hits single-product biotechs hardest. Here's how Madrigal is navigating it with the world's first approved MASH therapy. Large pharmaceutical companies are managing the risk that comes with the USA's Most Favoured Nation pricing policy across broad portfolios. Madrigal Pharmaceuticals has one commercial product. That asymmetry makes its European rollout one of the most closely watched access stories in the industry right now — because whatever Madrigal figures out, other single-asset biotechs will be watching. Rezdiffra is the first treatment ever approved specifically for MASH, a liver disease where more than 20 development programmes failed before it succeeded. Madrigal launched in Germany just 28 days after European Commission approval, exceptionally fast for a company of its size. Now it is working through reimbursement discussions across the Big Five European markets. Neil Archer, EVP International at Madrigal Pharmaceuticals, sat down with Roxane Höck to share the company's strategy in detail. He covers: - why the MASH patient population eligible for Rezdiffra is far smaller than the broader metabolic disease numbers suggest, and why that changes the reimbursement conversation - how Spain has become a model for linking clinical trial investment to medicine access, and what other markets can learn from it - and why Madrigal chose to build Poland directly rather than through a partner, and what that signals about its European ambitions Read more: https://lnkd.in/eURZxbxH
-
Juan Antonio T. a partagé ceciGood roles are not easy to find, but a good role and a great manager? Those are rare. ✨ If you're an IT Architect looking for your next move, do yourself a favor and check out this open position on Andrew's team. Working with Andrew at Madrigal will be a life opportunity! Take a look at the link below! 👇Juan Antonio T. a partagé ceciWe’re hiring a Director, IT Enterprise Architecture at Madrigal Pharmaceuticals. As our technology environment becomes more interconnected and complex, we are building enterprise architecture as a practical internal capability. This role will help create clearer standards, scalable roadmaps, and better cross-functional technology decisions as we scale. This is a hands-on architecture leadership role. We are looking for someone who can connect business strategy to technology decisions, operate across domains, and partner closely with teams to help the organization make pragmatic, durable decisions. If this sounds like you, or someone in your network, please take a look and share. https://lnkd.in/e86W7WuB #hiring #enterprisearchitecture #lifesciences #biotech #technology
-
Juan Antonio T. a republié ceciJuan Antonio T. a republié ceciCome and join our commercial Team in Zug!
-
Juan Antonio T. a republié ceciJuan Antonio T. a republié ceci🔥 Hot Off the Press 🔥 We’re building the future of biotech and it starts with you. Madrigal Pharmaceuticals is hiring a Senior Director, Agentic AI & Automation — a rare chance to build our Agentic Automation Center of Excellence from the ground up. You’ll: 1. Integrate LLMs, orchestration agents & hyper automation across Clinical, Commercial, Medical & Corporate teams. 2. Operationalize AI in a regulated, mission-driven environment—without losing agility 3. Drive culture-first automation to improve patient outcomes If you’re a systems thinker who thrives at the intersection of AI, change management & purpose—let’s talk. #MadrigalPharma #AIJobs #AgenticAI #AutomationWithPurpose #LLM #Leadership #CultureDriven #BiotechInnovation #TechWithHeart Madrigal Pharmaceuticals
-
Juan Antonio T. a republié ceciJuan Antonio T. a republié ceciGreat career opportunity to join Madrigal Pharmaceuticals team and leading with us the fight against MASH. Check this out #careeropportunities #pharmajobs #MASH #liverdisease
-
Juan Antonio T. a republié ceciJuan Antonio T. a republié ceciOur medical team is expanding, offering a fantastic career opportunity to join our Madrigal team. At Madrigal, every team member is united by our common goal: leading the fight against MASH. Join us in making a difference in healthcare. #MedicalTeam #CareerOpportunity #FightAgainstMASH #pharmajobs #MASH
-
Juan Antonio T. a republié ceciJuan Antonio T. a republié ceciNew hybrid role in Conshohocken, PA, for a technical expert in Medical Affairs technologies, focused on CRM, working with an incredible team, improving the lives of patients with MASH. Please apply or share!
-
Juan Antonio T. a partagé ceciExciting opportunity to join my team at Madrigal Pharmaceuticals! 🚀 Join our team as an IT Business Partner for the Commercial of the International Region at Madrigal Pharmaceuticals. We are seeking a commercially minded IT leader who can effectively connect technology with business. Are you enthusiastic about propelling commercial technology within the pharmaceutical industry? This role is tailor-made for individuals like you who are passionate about shaping the future of IT in the pharmaceutical industry. #ITBusinessPartner #CommercialExcellence #PharmaIndustry #Pharmajobs #Careerinpharma #CRM #Madrigal #MadrigalPharma #MadrigalPharmaceuticals
-
Juan Antonio T. a aimé ceciJuan Antonio T. a aimé ceciIf you’re a P4 PharmD student or recent graduate from an ACPE-accredited school of pharmacy interested in building a career in Medical Affairs, we’d love to meet you! In partnership with the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program, Madrigal just launched a two-year Medical Affairs Fellowship Program. Join us for an online informational session anytime between 5:30-9 p.m. ET on Monday, Sept. 28. Register and learn more: https://lnkd.in/gJNtFraK
-
Juan Antonio T. a aimé ceciJuan Antonio T. a aimé ceciI'm very excited to share that I've joined SenseMyDiet as Chief Commercial Officer. Built from a passion for healthy living and grounded in medical expertise, data and community feedback, SenseMyDiet is a daily partner and meal-planning coach for thousands of people striving to live healthier lives. Today, that foundation is also helping people on GLP-1 treatment succeed in everyday life. What immediately drew me to SenseMyDiet was not only the purpose, but the people behind it; a talented, ambitious and genuinely engaged team who really care about patient outcomes. When I was offered the opportunity to help accelerate SenseMyDiet's growth in Denmark and beyond by exploring new markets and opportunities, it just felt right. I'm excited to build on the strong foundation the team has already created and help turn the growth ambition into reality. Data, evidence and lived experience are at the heart of SenseMyDiet, and of my own passion for helping more women reach their full potential through every stage of life. If you're curious about how patient insights and real-world behaviour can help us better understand medication usage, adherence and engagement with health advice, I'd love to connect and share more about what SenseMyDiet can offer. I'm very much looking forward to the journey ahead and the collaboration with the SenseMyDiet team. Thank you Majken Brinkmann Søren Filbert Suzy Wengel Brian Trinhammer Seiling and Michael Clausen for the trust and opportunity.
-
Juan Antonio T. a aimé ceciJuan Antonio T. a aimé ceciMadrigal was proud to take part in last week’s Congressional Hispanic Leadership Institute Leadership Conference, which helped kick off #HispanicHeritageMonth with important conversations on policy challenges affecting Hispanic and Latino communities. Our presence at CHCI reflects our continued commitment to elevating awareness, advancing dialogue and supporting efforts to improve care for people living with MASH, including those in rural and underserved communities discussed during “Bridging the Distance: Bringing Quality Care and Innovation to Rural Communities.” This plenary session included Tony Martinez, MD, AAHIVS, FAASLD, Madrigal’s new Vice President of Hispanic Health Strategy, just 16 days into the job. Thank you to CHCI, our community stakeholders, advocacy partners and everyone involved in bringing these critical conversations forward. #CHCIHHM
-
Juan Antonio T. a aimé ceciJuan Antonio T. a aimé ceciI’ve joined Johnson & Johnson MedTech as Technology Director, MedTech Surgery, Emerging Markets. I’m looking forward to working with colleagues across Emerging Markets to advance the technology, digital, data and AI agenda in support of the business and the healthcare professionals and patients we ultimately serve. It also marks a return to Johnson & Johnson, making this next chapter particularly meaningful. #JohnsonAndJohnson #MedTech
-
Juan Antonio T. a aimé ceciJuan Antonio T. a aimé ceciWe’re excited to announce that Erin O'Hare has been nominated for the Woman of Impact in Life Sciences Award at Articulate 2026. 👏 With nearly two decades of experience across the pharmaceutical industry and management consulting, Erin has built a career spanning Medical Affairs, Commercial, and Market Access. As Senior Director, Global Operations and Medical Excellence at Madrigal Pharmaceuticals, she brings together strategic thinking and operational expertise to help teams navigate complex information and drive impactful initiatives across therapeutic areas. Erin represents the thoughtful, cross-functional leadership the Woman of Impact in Life Sciences Award celebrates. Congratulations, Erin, on this well-deserved nomination! Join us as we celebrate Erin and this year’s nominees at Articulate 2026: The Communication Revolution. 📅 October 1, 2026 📍 Museum of the American Revolution, Philadelphia Register here: https://lnkd.in/eU-qe53U #Articulate2026 #WomanOfImpact #LifeSciences #BioPharma #MedicalAffairs #Leadership #PrezentVivo
-
Juan Antonio T. a aimé ceciJuan Antonio T. a aimé ceciOur presence at the 12th annual #ParisMASH Meeting highlighted Madrigal’s continued commitment to leading the fight against MASH. Melinda Manley DAUMONT and Christina Parrinello, PhD, MPH presented posters spanning clinical, real-world and health-economic evidence, while Keith Miller shared Madrigal’s long-term vision during the Industry Corner. Together, these contributions reflect our focus on advancing scientific understanding and generating evidence that can help improve patient care.
-
Juan Antonio T. a aimé ceciJuan Antonio T. a aimé ceciVision made manifest! One of the reasons I founded my organization in 2014 was to attract innovation to solve problems that mattered to liver patients; and starting the NASH Council in 2017 to focus on fatty liver disease. Participating in the Grand Opening of the Madrigal Pharmaceuticals new global HQ in Pennsylvania surrounded by representatives from the PA economic and biotech innovation ecosystem was so meaningful. Seeing their commitment to patients front and center - literally in the wallpaper and incorporated in so many aspects of design - is one thing but witnessing their ongoing commitment across the patient community is even better. Leadership matters. Leadership lives here. Life Sciences Pennsylvania #biotech #pharmaceutical #patientadvocation #innovation
Expérience
Formation
Langues
-
Spanish
Bilingue ou langue natale
-
English
Capacité professionnelle complète
Voir le profil complet de Juan Antonio
-
Découvrir vos relations en commun
-
Être mis en relation
-
Contacter Juan Antonio directement
Autres profils similaires
Découvrir plus de posts
-
Carolina Matkosky
Medtronic • 2 k abonnés
Digital transformation rarely fails because of technology. It fails because leadership, culture, and organizational design don’t evolve with it. Over the past months I have been expanding my perspective on these topics through the Chief Digital Officer Program at MIT Professional Education. The program brings together leaders from different industries to explore how organizations can navigate digital transformation by aligning strategy, operating models, data, technology, and culture. One of the most valuable insights for me has been seeing how transformation happens at the intersection of innovation, leadership, and new ways of working. Technology can enable change, but leadership creates the conditions for teams to experiment, collaborate across functions, and deliver real impact. Coming from a background in operational excellence and global transformation, this experience has been helping me connect the worlds of Lean, digital transformation, and enterprise strategy in new ways. I look forward to continuing to apply these insights to help organizations design transformations that are both innovative and practical. #DigitalTransformation #Innovation #Leadership #OperationalExcellence #FutureOfWork #MITProfessionalEducation #ChiefDigitalOfficer
34
1 commentaire -
Dr. Timos Papagatsias
LucidQuest • 28 k abonnés
#LocationLocationLocation, a slogan that does not only apply to #RealEstate but also to other industries! 🗺️ Sometimes it is important to consider where #Pharmaceutical companies are physically located, especially when one needs to consider efficient and fast manufacturing and supply chains. 🚚💨 Check out a map we have built, listing the top companies in the #RadioPharmaceuticals space (also including companies manufacturing #RadioIsotopes). ☢️ Link to map: http://dlvr.it/TQc6F5 -- As you can see, the majority of companies are located in the United States 🇺🇸, with particular concentrations in #Massachusetts, #California, #Florida, and #Pennsylvania. This geographic concentration likely contributes to streamlined supply chains and faster delivery times within the country. Furthermore, this clustering suggests potential benefits for companies within these hubs, such as access to a skilled workforce and increased collaboration opportunities. However, our map also reveals an overall growing global presence in the #radiopharmaceutical industry. 🤔 -- Europe, for example, shows a notable concentration of companies in countries such as #Germany, #Belgium, #Italy, and the #Netherlands. -- The Asia-Pacific region is also witnessing a rise in companies, particularly in #Australia, #SouthKorea, #China, and #Japan. Let's keep the conversation going! What are your views on: 🤔 How can the radiopharmaceutical industry better address global health disparities and ensure equitable access to treatment, especially in lower-income countries? 🤔 What role can governments and regulatory bodies play in fostering innovation and growth in the radiopharmaceutical sector while ensuring safety and efficacy? 🤔 What are the ethical considerations surrounding the pricing and accessibility of radiopharmaceuticals, particularly for treatments like Targeted Alpha Therapy, and how can we strike a balance between innovation and affordability? 🔗 Stay tuned for more and like/share this post to see more like it! 📧 Reach out to #LucidQuest at info@lqventures.com to find out more about what we do and how we can support your brand to thrive! Lantheus PETNET Solutions-Winston-Salem POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Jubilant Pharma Limited Triadisotopes Global Medical Solutions Ratio Therapeutics AdvanCell Covidien (Medtronic Minimally Invasive Therapies Group) Avid Radiopharmaceuticals PharmaLogic Holdings Corp. PMB-ALCEN Monrol Nuclear Products Co. Novartis Niowave, Inc. Nucleus RadioPharma Bayer Telix Pharmaceuticals Limited Actinium Pharmaceuticals, Inc. Fusion Pharmaceuticals AstraZeneca Eli Lilly and Company RayzeBio 🤝 #PharmaLogistics #NuclearMedicine #Biotech #Insights
-
nexxar
3 k abonnés
#nowlive Another DAX-listed company is embracing digital reporting. Merck Group’s Annual Report 2025 is now live and presents the company’s performance in a clear and highly structured digital format. One standout feature is the large number of indices that guide readers through the report and connect the many regulatory frameworks and disclosures. As every year, the vibrant color concept gives the report a distinctive and modern visual identity. Explore the full report here: https://lnkd.in/djxkXzXS #Reporting #ReportingSeason #DigitalReport
19
-
Jan Burian
ARC Advisory Group Inc. • 20 k abonnés
🚨 Digital transformation in pharma isn’t about replacing everything at once - it’s about building a foundation for the future. In my latest report, I share how Almirall is accelerating its MES migration through IT/OT integration, standardized interoperability models (ISA-95), and a process-first approach. By using COPA-DATA’s zenon as an integration layer, the company is reducing complexity, enabling scalable connectivity, and preparing manufacturing for AI and future innovation. 💡Sometimes the goal is to make manufacturing “boring” - because predictable, standardized operations are what enable real digital transformation. Read the full article: https://lnkd.in/dqTF4xYk
11
1 commentaire -
Muhammad KHALID
Security Papers Limited (SPL) • 17 k abonnés
Are you still treating transformation like just another project? Project management is like piloting one plane — focused, time-bound, and measurable. But transformation? That’s like running the entire airline — it requires strategy, operations, culture, customer experience, and long-term sustainability. Too often, organizations confuse the two — and that’s why many transformations fail before they even take off. ✅ Launching a new ERP system = a project. ✅ Redefining how your company leverages data, upskilling employees, and reshaping decision-making = a transformation. ✅ Rolling out a new app = a project. ✅ Building a digital-first business model that changes how you serve customers = a transformation. Transformation goes beyond milestones; it’s about mindset, leadership alignment, and embedding change into the DNA of the organization. The lesson: Manage projects with precision. Lead transformations with vision. #Transformation #Leadership #ChangeManagement #DigitalTransformation #Strategy
13
4 commentaires -
Thomas Kipping, PhD
11 k abonnés
📊 A critical insight from Doug Benoit's latest analysis: healthcare doesn't need more data. It needs better ways to help clinicians identify what matters. Over 70% of healthcare professionals report that technology is being deployed faster than organizations can operationalize it. The solution isn't another AI tool. It's AI that filters noise, protects clinical attention, and keeps decision-making with humans. That's the real transformation. #Healthcare #IT #DigitalTransformation #ClinicalExcellence
7
1 commentaire -
Martin Dalek
Liebherr Group • 446 abonnés
A new thinktank paper on nine technology trends is extremely to the point: ...most of these shifts hit organizations now or within the next five years and will force “Peter”, the standard employee, to fundamentally adapt how he works – from executing tasks to supervising AI, handling exceptions and owning outcomes. At the same time, organizations must rapidly adjust structures, skills and governance so that people and technology evolve together rather than drifting apart – and the best part is that the paper explains this in a very easy-to-understand way while outlining a seamless roadmap for how to get started.
2
-
Gareth Lewis
AstraZeneca • 2 k abonnés
Meeting transcripts are now everywhere. But most teams are wasting them. If you prompt: “Summarise this meeting.” You’ll get something generic, forgettable and rarely useful. Instead, treat transcripts as strategic assets and productivity enablers. Prompt based on the audience and the outcome you need. Same transcript. Completely different value. The leverage isn’t in the recording. It’s in the prompt! Copy and paste prompts in the comments.... #GenAI #Productivity #Leadership #MeetingCulture #DigitalTransformation #FutureOfWork
59
5 commentaires -
Sebastien Carnel
Le Creuset • 2 k abonnés
I was proud to have a speech on October 6th in Basel 🎤. Here are my reflections from the Biotech X Forum last week: 🫀 Health systems now focus more than ever on outcomes that truly improve patients’ lives — being patient-centred, with individuals empowered to control their own health data. 🏭 The industrial model that built modern pharma — producing pills and vials at massive scale to ensure efficiency without compromising quality — still stands strong. Yet it faces mounting pressure: 💰 tighter margins, ⚖️ a delicate balance between shortages and costly inventories, ⏱️ the race to reduce time-to-market for innovations, 🚚 constant optimisation of distribution networks... Add to this the social and political strains from ageing populations, chronic diseases, and the growing challenge of financing longer lives. 💡 Many leaders at the Forum shared one conviction: if we truly care better — looking across the healthcare journey from R&D to consultation, treatment, remission, or stabilisation — we can unlock major gains in efficiency and outcomes, even quicker now thanks to AI 🤖. Indeed, I was struck by how deeply big tech players — AWS, Nvidia, Lenovo, Infosys, Capgemini, Deloitte, Microsoft, Snowflake, and many others — are investing in healthcare, from molecular modelling and protein simulation to AI-driven applications. Infosys, for instance, presented Ameca, the humanoid robot 🤖, as we discussed how biomarkers and wearable data are already reshaping clinical trials and patient monitoring. 🎯 My speech focused on our mission as life sciences manufacturers: to deliver the best products — and now, to pair them with the best digital services. The next frontier isn’t just technology — it’s experience and ethics: 🖥️ Tech giants have mastered experience, ⚖️ Ethics remains a work in progress. The digital patient journey is only beginning — deeply personal for each individual and a real productivity boost for HCPs and organisations. Traditional industry and tech must converge. For example, in automotive: Apple CarPlay and Android Auto are expected in about one-third of cars by 2025 🚗, with most drivers preferring them to built-in systems. Looking at social media — how close they came to making avatars our new selves and the metaverse our new world 🌐 — in a very different way, we see that digital care still has a technology to invent: one that makes the medical journey more specialised, productive, and humane. Yet in care, technological augmentation is never trivial — simulation, intelligence, precision, and computing power must serve better judgment and better guidance. How to measure ? 1. digital at scale, between global and local, 2. accelerate product life cycles with data, and 3. a digital forces fully integrated across all functions. Ultimately, digital success for patients won’t be measured by the number of clicks — but by the number of times we get care right ✅🙂 #BiotechXEurope #DigitalAndAICare #DigitalTransformation
44